# HDT Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hdt-bio

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.hdt.bio
- Total disclosed funding: $3M
- Latest round: Seed (Oct 5, 2020)
- Investors on record: 1

## About

HDT Bio Corp focuses on developing advanced RNA vaccines aimed at preventing and treating infectious diseases and cancers using innovative technology.Founded in 2018 and headquartered in Seattle, US, HDT Bio Corp is dedicated to advancing RNA vaccine technologies. The company has shifted strategies to enhance its vaccine development capabilities. The founding team includes Andre Lieber, Christopher Pirie, Darrick Carter, Neal Mody, and Steven Reed, with Steven Reed currently serving as CEO. In total, the company has completed 2 funding deals, with the latest being a GRANT of USD 2.9 mn received on May 17, 2021, from The National Institutes of Health. To date, HDT Bio has raised a total of USD 3.0 mn.HDT Bio specializes in advanced RNA vaccine products designed to prevent and treat infectious diseases and cancers, utilizing its proprietary LION™ technology. The company’s core offerings include self-amplifying RNA (repRNA) vaccines, which leverage the immune system's capabilities to enhance effectiveness against challenging medical conditions. These vaccines are particularly aimed at improving patient outcomes and addressing unmet medical needs in areas such as malaria and enterovirus-D68. HDT Bio serves a diverse client base, focusing on partnerships with clinical-stage vaccine companies like MalarVx, which recently licensed HDT's LION™ platform for malaria vaccine development. Geographically, HDT Bio's products are positioned to reach markets that require innovative vaccine solutions, particularly in regions impacted by infectious diseases, but specific market details are not disclosed.HDT Bio's revenue structure is primarily based on licensing agreements and partnerships with other organizations engaged in vaccine development. The company collaborates with entities like MalarVx, facilitating the use of its LION™ technology and repRNA platform in the creation of new vaccines. These transactions typically involve licensing fees and potential milestone payments as product development progresses. While specific pricing plans for individual products or services are not publicly detailed, the collaboration model implies a B2B transaction framework, where costs are determined through negotiated agreements between HDT Bio and its partners. Consequently, the revenue generation is directly linked to the success and commercialization of its innovative RNA vaccine offerings, particularly in the context of collaborative projects with external vaccine developers.HDT Bio Corp. plans to utilize the recent GRANT of USD 2.9 mn received from The National Institute of Allergy and Infectious Diseases to develop an HIV-1 RNA vaccine using its proprietary Lipid InOrganic Nanoparticle (LION) delivery system. The company aims to expand its product offerings and increase its market presence in the coming years, focusing on addressing critical health challenges and enhancing global vaccine accessibility.

## Funding rounds

- Seed, Oct 5, 2020, $3M — Zoic Capital

## Investors

- Zoic Capital (https://capitalatlas.ai/funds/zoic-capital) — Seed